MetaVia Inc. (MTVA)
| Market Cap | 13.71M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.55M |
| Shares Out | 19.59M |
| EPS (ttm) | -2.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,517 |
| Open | 0.7176 |
| Previous Close | 0.7180 |
| Day's Range | 0.7001 - 0.7199 |
| 52-Week Range | 0.6015 - 5.1600 |
| Beta | 0.21 |
| Analysts | Strong Buy |
| Price Target | 7.50 (+971.28%) |
| Earnings Date | Aug 13, 2025 |
About MTVA
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for MTVA stock is "Strong Buy." The 12-month stock price target is $7.5, which is an increase of 971.28% from the latest price.
News
MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose
Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass. , July 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiom...
MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session
CAMBRIDGE, Mass. , June 21, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation ...
MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as ...
MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions
CAMBRIDGE, Mass. , June 4, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract h...
MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update
Announced Positive Top-Line Phase 1 MAD Trial Results for DA-1726 in Obesity, Demonstrating Compelling Weight Loss and Best-in-Class Potential for Glucose Control, Waist Reduction and Tolerability Add...
MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
CAMBRIDGE, Mass. , May 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) ("MetaVia"), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a priva...
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025
DA-1241 Significantly Decreased Plasma ALT levels, with a Mean Reduction of 22.8 U/L After 16 Week-Treatment Controlled Attenuation Parameter (CAP) Score Improved by 23.0 dB/m, Indicating Reduced Live...
MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025
CAMBRIDGE, Mass. , April 23, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract...
MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential
A Dose-Dependent Response in Body Weight Reduction Was Observed Between 8 mg and 32 mg Doses Change in BMI and Body Weight Adjusted for Height In the Treatment Groups, Showed a Significant Difference ...
MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability
With No Titration, Demonstrated Compelling Maximum Weight Loss of 6.3% and Mean Weight Loss of 4.3% at Day 26 at 32 mg Dose (p=0.0005) Demonstrated Strong Signal of GLP-1R Efficacy with Maximum Lower...
MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update
Top-Line Data From MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in April of 2025 Announced Positive Top-Line 16-Week Results from the Phase 2a Trial of DA-1241 for the Treatment of MASH, in D...
MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference
CAMBRIDGE, Mass. , Jan. 10, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it is holdin...
NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases
New Nasdaq Ticker Symbol will be MTVA CAMBRIDGE, Mass. , Nov. 18, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming card...
NeuroBo Pharmaceuticals to Participate in Investor Conferences in November
CAMBRIDGE, Mass. , Nov. 13, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced ...
NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Reported Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity, Revealing Favorable Safety, Tolerability and Dose-Linear Pharmacokine...
NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Topline Data Readout From Part 1 and Part 2 Expected in December 2024 CAMBRIDGE, Mass. , Nov. 4, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology comp...
NeuroBo Pharmaceuticals to Participate in Investor Conferences in October
CAMBRIDGE, Mass. , Oct. 1, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced ...
NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Data Revealed Favorable Safety, Tolerability and Dose-Linear Pharmacokinetics (PK) Top-Line Data Readout from the MAD Part 2 Expected in the First Quarter of 2025 Planned Phase 1 Part 3 Will Evaluate ...
NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
CAMBRIDGE, Mass. , Sept. 3, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced ...
NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Successfully Completed a Financing of up to $70 Million, With $20 Million Upfront and an Additional $50 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-Based Warran...
NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
No Significant Issues Encountered During the Single Ascending Dose (SAD) Study, Allowing for Previously Reported Accelerated Start to Multiple Ascending Dose (MAD) Part 2 Top Line Data Readout from SA...
NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity
Collaboration to Leverage ImmunoForge's ELP Platform Technology Which Can Increase the Half-Life of a Drug by up to 200 Times CAMBRIDGE, Mass. , Aug. 6, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, I...
NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01
CAMBRIDGE, Mass. , July 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today a...
NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July
CAMBRIDGE, Mass. , July 11, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced ...
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Top-Line Data Readout From the Single Ascending Dose Part 1 Expected in the Third Quarter of 2024, and From the Multiple Ascending Dose Part 2 in the First Quarter of 2025 Planned Part 3 Will Assess T...